Fig. 5
Combination treatments efficiently reduce growth of A375-derived melanoma tumors in mice. NSG mice were injected subcutaneously with A375 cells (a) (n = 10 mice/group) and A375-XP cells (b) (n = 5 mice/group). After 14 days, when tumors were approximately 150 mm3, treatment was initiated (indicated by an arrow) by daily gavage (MK-1775, Wee1 inhibitor) or daily intraperitoneal injection (AZD7762, Chk inhibitor) or a combination of both inhibitors, for 8 consecutive days. Tumor growth was evaluated every second day and weights of extracted tumors were measured at end-point. The tumor volumes are presented relative to the tumor volume at the day before initiation of treatment. Data are presented as means ± SEM, *p < 0.05, **p < 0.01 ***p < 0.001 compared to vehicle-treated tumors. Comparison of tumor volumes was performed with a two-way ANOVA between groups followed by post-hoc Tukey’s multiple comparison tests